We assign a fundamental rating of 3 out of 10 to CTIC. CTIC was compared to 525 industry peers in the Biotechnology industry. CTIC may be in some trouble as it scores bad on both profitability and health. CTIC is valued quite expensively, but it does show have an excellent growth rating.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 94.11% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -27.07 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.27 | ||
| Quick Ratio | 1.26 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 22.47 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ChartMill assigns a fundamental rating of 3 / 10 to CTIC.
ChartMill assigns a valuation rating of 3 / 10 to CTI BIOPHARMA CORP (CTIC). This can be considered as Overvalued.
CTI BIOPHARMA CORP (CTIC) has a profitability rating of 1 / 10.
The financial health rating of CTI BIOPHARMA CORP (CTIC) is 1 / 10.